Abstract

Regenerative Medicine in Astellas

Yoshitsugu Shitaka, President, Astellas Institute for Regenerative Medicine

Astellas Institute for Regenerative Medicine (AIRM) was established in May 2016 following Astellas’ acquisition of Ocata Therapeutics. AIRM is an indirect, wholly owned subsidiary of Astellas and serves as Astellas’ global hub for RM and cell therapy in ophthalmology and other therapeutic areas that have few or no available treatment options.  The outline of Astellas RM will be reviewed in this presentation.